Nobody can deny that vaccination has been and will be one of the most profitable types of investments in healthcare, because it can significantly reduce government spending on the treatment of infectious diseases, and it also solves the problem of increasing the life expectancy of the country's population generally.
Meanwhile vaccine production is a long and expensive process. For example, the production of a solid dosage form can take about three weeks, while the production of a registered vaccine lasts from 24 to 36 months on average. The launch of a new vaccine in industrial production takes near 7 years. And in routine production, which, given the risks of each stage, is actually quite difficult to attribute to routine, and when working on a completely new product, the company must be sure that the vaccine will be in demand by the main customer - the state.
Effective measures to support vaccine manufacturers are long-term contracts. For example, a guarantee of sales of drugs in the case of already organized production may be three-year contracts in the framework of tender procedures. The funds received will ensure timely production planning and stabilize prices for its duration.
The capacity of the commercial segment of vaccines is limited today. There is no local production of a seceral of drugs. In the case of a new development, we can safely say that to ensure the National calendar of preventive vaccinations, we are talking about a one-on-one partnership between the state and the local manufacturer. Therefore, for projects at the stage of antigen development, the guarantee of marketing of the future vaccine should be valid for 5 years or more.
If producers do not have such guarantees in the near future, then it will be difficult for companies to invest their own funds in development and production. And innovations in a product such as a vaccine are constantly required, nature itself dictates the need for continuous scientific research.
If support measures are taken, the state will make the most profitable investment and create a guarantee that the country's population will be fully provided with high-quality domestic drugs, which in the future will also have export potential.
The development and production of vaccines will reduce significant costs for the treatment of infection. So, the annual economic damage from chickenpox is about 29 billion rubles. Human HPV - more than 20 billion rubles. These funds may remain in the state budget. In our opinion, such savings are worth considering the issue of support for manufacturers.
Long-term contracts will not only ensure the economic stability of our own production, but also contribute to the development of innovative products. And the main thing is to fulfill the requirements of the state itself: the formation of the country's immunobiological security.
